This article was originally published on the World Bank’s blog. Below is an excerpt.
Below, we lay out the four key elements to consider when planning an end-to-end vaccination deployment.
1. Vaccine Strategy
Vaccine strategies hinge on governments defining clear objectives for the short, medium, and long terms. These objectives help to define the priority populations for vaccination, which vaccines are most appropriate in the national context, expected supply and demand, deployment requirements, and possible scenarios that may play out. Strategies must be supported with appropriate regulations, an operational plan and a good monitoring system to track progress of the vaccination campaign to ensure efficient and equitable access.
While the need to procure vaccines is pressing, each vaccine has its own deployment implications including prices, regimen, storage, transportation, and administration. Procurement decisions must be informed by assessments of such deployment implications and the country’s health system capacity. For example, some countries have chosen vaccines which do not require ultra-cold chain.
Supply chain readiness is a critical issue for all countries — existing immunization supply chains might not be well equipped to manage the distribution of COVID-19 vaccines. Three key issues to consider are cold chain sufficiency, last mile logistics, and ancillary supplies. Some of the “wave 1” vaccine candidates have highly stringent supply chain requirements such as ultra-cold chain. Even for vaccines that have standard cold chain requirements, challenges include matching vaccine doses with ancillary supplies, enabling traceability of scarce resources, ensuring supply availability for administration of second dose, and enabling throughput of volumes higher than standard immunization campaigns.
Strengthening the health system is central to efficient distribution. Countries must consider levers to rapidly mobilize the health workforce for vaccination and enhance data systems required for vaccine and beneficiary tracking and ongoing pharmacovigilance.
Community acceptance of, and demand for, vaccines must be improved through well designed communication campaigns taking into account behavioral insights. Targeted communications for selected population segments may be needed to address misinformation and misperceptions.
Governments should estimate the total costs for vaccine procurement and distribution in different scenarios and plan accordingly. On the basis of costing, an analysis of fiscal space should be conducted. Central to this is an assessment of options and tradeoffs for mobilizing domestic and external funds, including opportunity costs, considering the need to maintain a balanced vaccine portfolio.
However, there are key uncertainties inherent to rolling out a new vaccine, for which contingencies must be made. For example, costs would significantly increase in cases of a shorter than expected duration of vaccine protection or weaker vaccine protection against emerging variants.
Read the blog in full here.